BMS says it will take an additional year to meet its target for new drugs.

Published Date: 28 Oct 2023

In light of the longer than anticipated sales ramp-up of medications like the multiple sclerosis drug Zeposia and the psoriasis treatment Sotyktu, Bristol Myers Squibb on Thursday pushed back by a year the timeline for its new-product portfolio to reach $10 billion in revenue.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Examines Office-Based Transperineal Prostate Biopsies Methodology.

2.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

3.

Is a $2,000 Whole-Body MRI Worth It?

4.

Surgery may not be necessary to treat invasive breast cancer

5.

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot